Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Galecto (GLTO – Research Report), Encompass Health (EHC – Research Report) and Caribou Biosciences (CRBU – Research Report).
Galecto (GLTO)
Galecto received a Hold rating from H.C. Wainwright analyst Boobalan Pachaiyappan today. The company’s shares closed last Wednesday at $0.70, close to its 52-week low of $0.54.
According to TipRanks.com, Pachaiyappan is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Galecto with a $5.67 average price target.
See the top stocks recommended by analysts >>
Encompass Health (EHC)
In a report released yesterday, Ben Hendrix from RBC Capital reiterated a Buy rating on Encompass Health, with a price target of $83.00. The company’s shares closed last Wednesday at $67.11.
According to TipRanks.com, Hendrix has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Encompass Health with a $79.56 average price target, which is a 17.8% upside from current levels. In a report released today, Bank of America Securities also maintained a Buy rating on the stock with a $84.00 price target.
Caribou Biosciences (CRBU)
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Caribou Biosciences today and set a price target of $23.00. The company’s shares closed last Wednesday at $4.69, close to its 52-week low of $3.96.
According to TipRanks.com, Burns has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Caribou Biosciences is a Strong Buy with an average price target of $22.83.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GLTO:
- Galecto Announces Plans to Explore Strategic Alternatives
- Galecto to explore strategic alternatives, reduce workforce by 70%
- Galecto to Present at Investor Conferences in September
- Galecto price target lowered to $2 from $12 at H.C. Wainwright
- SVB downgrades Galecto after ‘disappointing’ GB0139 results
